Welcome to LookChem.com Sign In|Join Free
  • or
Phosphonium, [[4-(methoxycarbonyl)phenyl]methyl]triphenyl- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

18312-77-1

Post Buying Request

18312-77-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

18312-77-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 18312-77-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,3,1 and 2 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 18312-77:
(7*1)+(6*8)+(5*3)+(4*1)+(3*2)+(2*7)+(1*7)=101
101 % 10 = 1
So 18312-77-1 is a valid CAS Registry Number.

18312-77-1Downstream Products

18312-77-1Relevant academic research and scientific papers

Structure-Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt

Meijer, Femke A.,Saris, Annet O.W.M.,Doveston, Richard G.,Oerlemans, Guido J.M.,De Vries, Rens M.J.M.,Somsen, Bente A.,Unger, Anke,Klebl, Bert,Ottmann, Christian,Cossar, Peter J.,Brunsveld, Luc

, p. 9238 - 9258 (2021)

The inhibition of the nuclear receptor retinoic-acid-receptor-related orphan receptor γt (RORγt) is a promising strategy in the treatment of autoimmune diseases. RORγt features an allosteric binding site within its ligand-binding domain that provides an opportunity to overcome drawbacks associated with orthosteric modulators. Recently, trisubstituted isoxazoles were identified as a novel class of allosteric RORγt inverse agonists. This chemotype offers new opportunities for optimization into selective and efficacious allosteric drug-like molecules. Here, we explore the structure-activity relationship profile of the isoxazole series utilizing a combination of structure-based design, X-ray crystallography, and biochemical assays. The initial lead isoxazole (FM26) was optimized, resulting in compounds with a ~10-fold increase in potency (low nM), significant cellular activity, promising pharmacokinetic properties, and a good selectivity profile over the peroxisome-proliferated-activated receptor γand the farnesoid X receptor. We envisage that this work will serve as a platform for the accelerated development of isoxazoles and other novel chemotypes for the effective allosteric targeting of RORγt.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 18312-77-1